What must clinical investigators disclose under the FDA Guidance for Advisory Committee Members and Staff?

Clinical investigators are required to disclose any financial interest in the sponsor, drug, or device under the FDA Guidance for Advisory Committee Members and Staff. This requirement is crucial because it helps to ensure transparency in the advisory process and addresses potential conflicts of interest that could influence the outcomes of clinical investigations or recommendations made by the advisory committees.

The emphasis on any financial interest, rather than just specific types of financial support or investments, reflects the FDA's commitment to maintaining the integrity of the advisory committees. Disclosing a broad range of financial interests, including direct funding, consultancy payments, ownership stakes, and other vested interests, provides a comprehensive view of any potential biases that may affect an investigator's objectivity.

The other options mention specific conditions that do not encompass the full scope of the disclosure requirements set by the FDA, which is aimed at uncovering all possible conflicts that could arise from any type of financial relationship with sponsors or related entities.